Subacute cutaneous lupus erythematosus and its association with drugs: A population-based matched case-control study of 234 patients in Sweden

British Journal of Dermatology

Volumn 167, Issue 2, 2012, Pages 296-305

  Gronhagen C M ^a   Fored, C M ^b   Linder, M ^b   Granath, F ^b   Nyberg, F ^a,c  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ADALIMUMAB; ALPHA INTERFERON; ANASTROZOLE; BETA INTERFERON; BROMPHENIRAMINE; CAPECITABINE; CARBAMAZEPINE; DILTIAZEM; DOCETAXEL; DOXORUBICIN; EFALIZUMAB; ETANERCEPT; LEFLUNOMIDE; LEUPRORELIN; METHOTREXATE; NIFEDIPINE; NITRENDIPINE; OXPRENOLOL; PACLITAXEL; PHENYTOIN; PIROXICAM; RANITIDINE; SIMVASTATIN; TAMOXIFEN; TERBINAFINE; THIAZIDE DIURETIC AGENT; TICLOPIDINE; UNINDEXED DRUG; VERAPAMIL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; SKIN LUPUS ERYTHEMATOSUS; SWEDEN; TREATMENT DURATION;

EID: 84864413440     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10969.x     Document Type: Article

References (87)

1. Marzano AV, Vezzoli P, Crosti C,. Drug-induced lupus: an update on its dermatologic aspects. Lupus 2009; 18: 935-40.
2. Callen JP,. Drug-induced subacute cutaneous lupus erythematosus. Lupus 2010; 19: 1107-11.
3. Lowe G, Henderson CL, Grau RH, et al. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2011; 164: 465-72.
4. Sontheimer RD, Thomas JR, Gilliam JN,. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979; 115: 1409-15.
5. Grönhagen CM, Fored CM, Granath F, Nyberg F,. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol 2011; 164: 1335-41.
6. Johansson-Stephansson E, Koskimies S, Partanen J, Kariniemi AL,. Subacute cutaneous lupus erythematosus. Genetic markers and clinical and immunological findings in patients. Arch Dermatol 1989; 125: 791-6.
7. Marzano AV, Lazzari R, Polloni I, et al. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol 2011; 165: 335-41.
8. Lin JH, Dutz JP, Sontheimer RD, Werth VP,. Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol 2007; 33: 85-106.
9. Walling HW, Sontheimer RD,. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009; 10: 365-81.
10. Cardinali C, Caproni M, Bernacchi E, et al. The spectrum of cutaneous manifestations in lupus erythematosus-the Italian experience. Lupus 2000; 9: 417-23.
11. Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985; 103: 49-51.
12. David-Bajar KM,. Subacute cutaneous lupus erythematosus. J Invest Dermatol 1993; 100: S2-8.
13. Guhl G, Diaz-Ley B, Garcia-Garcia C, et al. Chemotherapy-induced subacute lupus erythematosus. Lupus 2009; 18: 859-60.
14. Funke AA, Kulp-Shorten CL, Callen JP,. Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy. Arch Dermatol 2010; 146: 1113-16.
15. Sontheimer RD, Henderson CL, Grau RH,. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 2009; 301: 65-70.
16. Chang C, Gershwin ME,. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 2011; 34: 357-74.
17. Socialstyrelsen. Kodningskvalitet i Patientregistret- Slutenvård 2007. Stockholm: Socialstyrelsen, 2009.
18. Bjornadal L, Lofstrom B, Yin L, et al. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002; 31: 66-71.
19. Stephansson O, Kieler H, Granath F, Falconer H,. Endometriosis, assisted reproduction technology, and risk of adverse pregnancy outcome. Hum Reprod 2009; 24: 2341-7.
20. Socialstyrelsen. Kvalitet och InnehÃ¥ll i Patientregistret: Utskrivningar frÃ¥n SlutenvÃ¥rden 1964-2007 och Besök i Specialiserad ÖppenvÃ¥rd (Exklusive PrimärvÃ¥ rdsbesök) 1997-2007. Stockholm: Socialstyrelsen, 2009.
21. Barlow L, Westergren K, Holmberg L, Talback M,. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009; 48: 27-33.
22. Nilsson AC, Spetz CL, Carsjo K, et al. [Reliability of the hospital registry. The diagnostic data are better than their reputation]. Lakartidningen 1994; 91: 598.
23. Swedish National Board of Health and Welfare. Official Statistics of Sweden, Pharmaceuticals-Statistics for 2010. Stockholm: Swedish National Board of Health and Welfare, 2011.
24. Hirji KF, Tsiatis AA, Mehta CR,. Median unbiased estimation for binary data. Am Stat 1989; 43: 7-11.
25. Coughlin SS, Benichou J, Weed DL,. Attributable risk estimation in case-control studies. Epidemiol Rev 1994; 16: 51-64.
26. Kasperkiewicz M, Anemuller W, Angelova-Fischer I, et al. Subacute cutaneous lupus erythematosus associated with terbinafine. Clin Exp Dermatol 2009; 34: e403-4.
27. Lorentz K, Booken N, Goerdt S, Goebeler M,. Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature. J Dtsch Dermatol Ges 2008; 6: 823-7.
28. Neovius M, Sundstrom A, Simard J, et al. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scand J Rheumatol 2011; 40: 8-15.
29. Spillane AP, Xia Y, Sniezek PJ,. Drug-induced lupus erythematosus in a patient treated with adalimumab. J Am Acad Dermatol 2007; 56 (Suppl.): S114-16.
30. Martin JM, Ricart JM, Alcacer J, et al. Adalimumab-induced lupus erythematosus. Lupus 2008; 17: 676-8.
31. Tebbe B, Orfanos CE,. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus 1997; 6: 96-104.
32. Vedove CD, Del Giglio M, Schena D, Girolomoni G,. Drug-induced lupus erythematosus. Arch Dermatol Res 2009; 301: 99-105.
33. Gunnarsson I, Kanerud L, Pettersson E, et al. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol 1997; 36: 1089-94.
34. Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003; 139: 45-9.
35. Spiera RF, Berman RS, Werner AJ, Spiera H,. Ticlopidine-induced lupus: a report of 4 cases. Arch Intern Med 2002; 162: 2240-3.
36. Reich A, Bialynicki-Birula R, Szepietowski JC,. Drug-induced subacute cutaneous lupus erythematosus resulting from ticlopidine. Int J Dermatol 2006; 45: 1112-14.
37. Schoonen WM, Thomas SL, Somers EC, et al. Do selected drugs increase the risk of lupus? A matched case-control study. Br J Clin Pharmacol 2010; 70: 588-96.
38. Uetrecht J,. Current trends in drug-induced autoimmunity. Autoimmun Rev 2005; 4: 309-14.
39. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-33.
40. Panting KJ, Pinto M, Ellison J,. Lansoprazole-induced subacute cutaneous lupus erythematosus. Clin Exp Dermatol 2009; 34: 733-4.
41. Parodi A, Romagnoli M, Rebora A,. Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide. Photodermatology 1989; 6: 100-2.
42. Darken M, McBurney EI,. Subacute cutaneous lupus erythematosus-like drug eruption due to combination diuretic hydrochlorothiazide and triamterene. J Am Acad Dermatol 1988; 18: 38-42.
43. Brown CW Jr, Deng JS,. Thiazide diuretics induce cutaneous lupus-like adverse reaction. J Toxicol Clin Toxicol 1995; 33: 729-33.
44. Gange RW, Levene GM,. A distinctive eruption in patients receiving oxprenolol. Clin Exp Dermatol 1979; 4: 87-97.
45. Fenniche S, Dhaoui A, Ammar FB, et al. Acebutolol-induced subacute cutaneous lupus erythematosus. Skin Pharmacol Physiol 2005; 18: 230-3.
46. Crowson AN, Magro CM,. Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy. Hum Pathol 1997; 28: 67-73.
47. Crowson AN, Magro CM,. Diltiazem and subacute cutaneous lupus erythematosus-like lesions. N Engl J Med 1995; 333: 1429.
48. Kurtis B, Larson MJ, Hoang MP, Cohen JB,. Case report: verapamil-induced subacute cutaneous lupus erythematosus. J Drugs Dermatol 2005; 4: 506-8.
49. Gubinelli E, Cocuroccia B, Girolomoni G,. Subacute cutaneous lupus erythematosus induced by nifedipine. J Cutan Med Surg 2003; 7: 243-6.
50. Marzano AV, Borghi A, Mercogliano M, et al. Nitrendipine-induced subacute cutaneous lupus erythematosus. Eur J Dermatol 2003; 13: 213-16.
51. Patri P, Nigro A, Rebora A,. Lupus erythematosus-like eruption from captopril. Acta Derm Venereol (Stockh) 1985; 65: 447-8.
52. Fernandez-Diaz ML, Herranz P, Suarez-Marrero MC, et al. Subacute cutaneous lupus erythematosus associated with cilazapril. Lancet 1995; 345: 398.
53. Noel B, Panizzon RG,. Lupus-like syndrome associated with statin therapy. Dermatology 2004; 208: 276-7.
54. Suchak R, Benson K, Swale V,. Statin-induced Ro/SSa-positive subacute cutaneous lupus erythematosus. Clin Exp Dermatol 2007; 32: 589-91.
55. Bracke A, Nijsten T, Vandermaesen J, et al. Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases. Acta Derm Venereol (Stockh) 2005; 85: 353-4.
56. Dam C, Bygum A,. Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors. Acta Derm Venereol (Stockh) 2008; 88: 87-9.
57. Toms-Whittle LM, John LH, Buckley DA,. Drug-induced subacute cutaneous lupus erythematosus associated with omeprazole. Clin Exp Dermatol 2011; 36: 281-3.
58. Mankia SK, Rytina E, Burrows NP,. Omeprazole-induced subacute cutaneous lupus erythematosus. Clin Exp Dermatol 2010; 35: e1-2.
59. Popovic K, Wahren-Herlenius M, Nyberg F,. Clinical follow-up of 102 anti-Ro/SSA-positive patients with dermatological manifestations. Acta Derm Venereol (Stockh) 2008; 88: 370-5.
60. Roura M, Lopez-Gil F, Umbert P,. Systemic lupus erythematosus exacerbated by piroxicam. Dermatologica 1991; 182: 56-8.
61. Hivnor CM, Hudkins ML, Bonner B,. Terbinafine-induced subacute cutaneous lupus erythematosus. Cutis 2008; 81: 156-7.
62. Miyagawa S, Okuchi T, Shiomi Y, Sakamoto K,. Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin. J Am Acad Dermatol 1989; 21: 343-6.
63. Capponi A, De Simone C, Guerriero C, et al. Ro/SSA-positive cutaneous lupus erythematosus induced by carbamazepine. Arch Dermatol 2005; 141: 103-4.
64. Amerio P, Innocente C, Feliciani C, et al. Drug-induced cutaneous lupus erythematosus after 5 years of treatment with carbamazepine. Eur J Dermatol 2006; 16: 281-3.
65. Ross S, Ormerod AD, Roberts C, et al. Subacute cutaneous lupus erythematosus associated with phenytoin. Clin Exp Dermatol 2002; 27: 474-6.
66. Bleumink GS, ter Borg EJ, Ramselaar CG, Stricker BHC,. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2001; 40: 1317-19.
67. Williams VL, Cohen PR,. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011; 50: 619-25.
68. Bentley DD, Graves JE, Smith DI, Heffernan MP,. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2006; 54 (Suppl.): S242-3.
69. Sheth N, Greenblatt D, Patel S, Acland K,. Adalimumab-induced cutaneous lupus. Clin Exp Dermatol 2007; 32: 593-4.
70. Chen M, Crowson AN, Woofter M, et al. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 2004; 31: 818-20.
71. Adachi A, Horikawa T,. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. J Dermatol 2007; 34: 473-6.
72. Fumal I, Danchin A, Cosserat F, et al. Subacute cutaneous lupus erythematosus associated with tamoxifen therapy: two cases. Dermatology 2005; 210: 251-2.
73. Fernandes NF, Rosenbach M, Elenitsas R, Kist JM,. Subacute cutaneous lupus erythematosus associated with capecitabine monotherapy. Arch Dermatol 2009; 145: 340-1.
74. Weger W, Kranke B, Gerger A, et al. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine. J Am Acad Dermatol 2008; 59 (Suppl. 1): S4-6.
75. Marzano AV, Ramoni S, Del Papa N, et al. Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. Lupus 2008; 17: 329-31.
76. Chan SK, Hazleman BL, Burrows NP,. Subacute cutaneous lupus erythematosus precipitated by leflunomide. Clin Exp Dermatol 2005; 30: 724-5.
77. Kerr OA, Murray CS, Tidman MJ,. Subacute cutaneous lupus erythematosus associated with leflunomide. Clin Exp Dermatol 2004; 29: 319-20.
78. Gensburger D, Kawashima M, Marotte H, et al. Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis 2005; 64: 153-5.
79. Goeb V, Berthelot JM, Joly P, et al. Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2005; 44: 823-4.
80. Elias AR, Tam CC, David-Bajar KM,. Subacute cutaneous lupus erythematosus associated with leflunomide. Cutis 2005; 76: 189-92.
81. Nousari HC, Kimyai-Asadi A, Tausk FA,. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet 1998; 352: 1825-6.
82. Wiechert A, Tuting T, Bieber T, et al. Subacute cutaneous lupus erythematosus in a leuprorelin-treated patient with prostate carcinoma. Br J Dermatol 2008; 159: 231-3.
83. Trancart M, Cavailhes A, Balme B, Skowron F,. Anastrozole-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2008; 158: 628-9.
84. Crowson AN, Magro CM,. Lichenoid and subacute cutaneous lupus erythematosus-like dermatitis associated with antihistamine therapy. J Cutan Pathol 1999; 26: 95-9.
85. Toll A, Campo-Pisa P, Gonzalez-Castro J, et al. Subacute cutaneous lupus erythematosus associated with cinnarizine and thiethylperazine therapy. Lupus 1998; 7: 364-6.
86. Cassis TB, Callen JP,. Bupropion-induced subacute cutaneous lupus erythematosus. Australas J Dermatol 2005; 46: 266-9.
87. Pham HC, Saurat JH,. Inhalation route inducing subacute cutaneous lupus erythematosus with tiotropium. Arch Dermatol 2005; 141: 911-12.